Literature DB >> 8163942

Immunologically nonspecific mechanisms of tissue destruction in the rejection of skin grafts.

D P Doody1, K S Stenger, H J Winn.   

Abstract

When mice are lethally irradiated and reconstituted with allogeneic bone marrow cells, their skin is repopulated over a period of several months with Langerhans cells (LC) of marrow donor origin. Skin from such mice, when transplanted to unirradiated syngeneic recipients, became in many cases the sites of intense inflammatory responses that led to varying degrees of destruction of the transplanted skin and in some instances, to rejection of the entire graft. The frequency and intensity of these responses were influenced by the nature of the immunogenetic disparity between the donors and recipients of the marrow cells. Chimeric skin placed on hybrid mice derived from crosses between the marrow donors and recipients behaved in all respects as syngeneic grafts or autografts. When the recipients of the chimeric skin were presensitized to the antigens of the marrow donor, the responses were especially intense, and resulted in all cases in complete rejection. Thus the immunologically mediated attack on the allogeneic LCs was accompanied by widespread and nonspecific destruction of bystander cells. In all cases, the inflammation and tissue damage were confined sharply to the grafted skin, showing clearly that nonspecific or indirect tissue destruction is entirely consistent with highly selective destruction of grafted tissues. This finding removes a major objection to postulated mechanisms of rejection that involve indirect destruction of grafted tissues.

Entities:  

Mesh:

Year:  1994        PMID: 8163942      PMCID: PMC2191467          DOI: 10.1084/jem.179.5.1645

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  The homograft reaction.

Authors:  G D SNELL
Journal:  Annu Rev Microbiol       Date:  1957       Impact factor: 15.500

2.  Cellular pathways for rejection of class-I-MHC--disparate skin and tumor allografts.

Authors:  D M Smith; F P Stuart; G A Wemhoff; J Quintáns; F W Fitch
Journal:  Transplantation       Date:  1988-01       Impact factor: 4.939

3.  Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response.

Authors:  H F Dvorak; M C Mihm; A M Dvorak; R A Johnson; E J Manseau; E Morgan; R B Colvin
Journal:  Lab Invest       Date:  1974-08       Impact factor: 5.662

4.  Histocompatibility antigens on melanoblasts and hair follicle cells. Cell-localized homograft rejection in allophenic skin grafts.

Authors:  B Mintz; W K Silvers
Journal:  Transplantation       Date:  1970-05       Impact factor: 4.939

5.  Bone marrow-derived cells are responsible for stimulation I region-incompatible skin graft rejection.

Authors:  J G Woodward; B L Shigekawa; J A Frelinger
Journal:  Transplantation       Date:  1982-03       Impact factor: 4.939

6.  Passenger leukocytes and the immunogenicity of skin allografts.

Authors:  D Steinmuller
Journal:  J Invest Dermatol       Date:  1980-07       Impact factor: 8.551

7.  The vascular bed as the primary target in the destruction of skin grafts by antiserum. I. Resistance of freshly placed xenografts of skin to antiserum.

Authors:  S V Jooste; R B Colvin; W D Soper; H J Winn
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

8.  Strong cellular immune responses induced in vivo against minor antigens in the mouse.

Authors:  J F Burdick
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

9.  The vascular bed as the primary target in the destruction of skin grafts by antiserum. II. Loss of sensitivity to antiserum in long-term xenografts of skin.

Authors:  S V Jooste; R B Colvin; H J Winn
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

10.  Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response.

Authors:  H F Dvorak; M C Mihm; A M Dvorak; B A Barnes; E J Manseau; S J Galli
Journal:  J Exp Med       Date:  1979-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.